Evidence map›Paper›PMID 17668051›Full record

ArticlePloS one2007

Engineering the melanocortin-4 receptor to control constitutive and ligand-mediated G(S) signaling in vivo.

Supriya Srinivasan, Pamela Santiago, Cecile Lubrano, Christian Vaisse, Bruce R Conklin

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Remote control of neuronal signaling.Pharmacological reviews · 2011
    Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Supriya SrinivasanGladstone Institute of Cardiovascular Disease, University of California at San Francisco, San Francisco, California, United States of America. supriya.srinivasan@ucsf.edu
Pamela Santiago
Cecile Lubrano
Christian Vaisse
Bruce R Conklin
Gladstone Institutes · USUniversity of California, San Francisco · US

Funding

The Melanocortin-4 Receptor in Human ObesityR01DK060540 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHRISTIAN VAISSE · 2002 to 2026
$7.5M
Tissue Engineering with a Modular RASSL ToolboxR01HL060664 · NHLBI · J. DAVID GLADSTONE INSTITUTES · PI CONKLIN, BRUCE R · 1998 to 2012
$7.0M
NHLBI NIH HHS HL60664-06NHLBI NIH HHS R01 HL060664NIDDK NIH HHS R01 DK060540
6 · The paper itself

Abstract

The molecular and functional diversity of G protein-coupled receptors is essential to many physiological processes. However, this diversity presents a significant challenge to understanding the G protein-mediated signaling events that underlie a specific physiological response. To increase our understanding of these processes, we sought to gain control of the timing and specificity of G(s) signaling in vivo. We used naturally occurring human mutations to develop two G(s)-coupled engineered receptors that respond solely to a synthetic ligand (RASSLs). Our G(s)-coupled RASSLs are based on the melanocortin-4 receptor, a centrally expressed receptor that plays an important role in the regulation of body weight. These RASSLs are not activated by the endogenous hormone alpha-melanocyte-stimulating hormone but respond potently to a selective synthetic ligand, tetrahydroisoquinoline. The RASSL variants reported here differ in their intrinsic basal activities, allowing the separation of the effects of basal signaling from ligand-mediated activation of the G(s) pathway in vivo. These RASSLs can be used to activate G(s) signaling in any tissue, but would be particularly useful for analyzing downstream events that mediate body weight regulation in mice. Our study also demonstrates the use of human genetic variation for protein engineering.

Indexed as

alpha-MSHAmino Acid SequenceCell LineCell MembraneCyclic AMPHeterozygoteHumansKidneyKineticsModels, MolecularMolecular Sequence DataObesityPoint MutationProtein ConformationProtein EngineeringReceptor, Melanocortin, Type 4alpha-MSHCyclic AMPMC4R protein, humanN-(1,2,3,4-tetrahydroisoquinolinium-3-ylcarbonyl)-1-(4-chlorobenzyl)-2-(4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl)-2-oxoethylamineReceptor, Melanocortin, Type 4TetrahydroisoquinolinesTriazoles

Identifiers

PMID17668051
PMCPMC1930153
OpenAlexW1995991411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.